Drugs / Typhoid Vi polysaccharide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01608815 | May → Sep 2012 | typhoid fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00875524 Comparator | Mar 2009 → Aug 2014 | Dengue hemorrhagic fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Typhoid Vi polysaccharide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00875524 ↗ |
| Modality | Vaccine | “Participants who received the Meningococcal Polysaccharide Vaccine A + C, placebo, and Typhoid Vi polysaccharide vaccine as the first (Day 0), second (Day 0 + 6 months), and...” NCT00875524 ↗ |
| Route | Intramuscular | “0.5 mL, Intramuscular” NCT01608815 ↗ |